Literature DB >> 8929785

D-penicillamine-induced myositis in rheumatoid arthritis.

R Chappel1, J Willems.   

Abstract

D-penicillamine, an agent still used in the treatment of rheumatoid arthritis (RA) may produce inflammatory myopathy or myositis. Some reported cases are documented with muscle biopsy. We report a 34-year old female, receiving the drug for more than 4 years, who consulted us with recently developed proximal muscle pain and weakness. EMG-findings were typical for inflammatory muscle disease; muscle enzymes remained normal. D-penicillamine was stopped and she was started on prednisolone with rapid improvement. The EMG-findings, with follow-up within three months, proved to be a good diagnostic tool, in the absence of laboratory muscle enzymes abnormalities.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8929785     DOI: 10.1007/bf02231694

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  5 in total

1.  D-penicillamine-induced polymyositis in rheumatoid arthritis.

Authors:  B G Cucher; A L Goldman
Journal:  Ann Intern Med       Date:  1976-11       Impact factor: 25.391

2.  [Myositis or non-inflammatory myopathy: an EMG diagnosis?].

Authors:  F Heistercamp; M Francx; P Herregods; F Defoer; L Joris; C Mahler; R Chappel
Journal:  Acta Belg Med Phys       Date:  1988 Jul-Sep

3.  D-penicillamine induced myasthenia gravis in rheumatoid arthritis: an unpredictable common occurrence?

Authors:  A P Andonopoulos; E Terzis; E Tsibri; C A Papasteriades; T Papapetropoulos
Journal:  Clin Rheumatol       Date:  1994-12       Impact factor: 2.980

4.  Dermatomyositis complicating penicillamine treatment.

Authors:  L Fernandes; D R Swinson; E B Hamilton
Journal:  Ann Rheum Dis       Date:  1977-02       Impact factor: 19.103

5.  Penicillamine-induced myositis in rheumatoid arthritis.

Authors:  G J Morgan; J L McGuire; J Ochoa
Journal:  Muscle Nerve       Date:  1981 Mar-Apr       Impact factor: 3.217

  5 in total
  3 in total

Review 1.  Beyond the joints: neurological involvement in rheumatoid arthritis.

Authors:  Cesar Ramos-Remus; Sergio Duran-Barragan; Jose Dionisio Castillo-Ortiz
Journal:  Clin Rheumatol       Date:  2011-09-20       Impact factor: 2.980

2.  Rapid progression of scleroderma possibly associated with penicillamine therapy.

Authors:  Y S Haviv; R Safadi
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

Review 3.  Toxic myopathies.

Authors:  Mamatha Pasnoor; Richard J Barohn; Mazen M Dimachkie
Journal:  Neurol Clin       Date:  2014-08       Impact factor: 3.806

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.